The BSRBR-RA study tracks the progress of people with rheumatoid arthritis (RA) who have been prescribed biologic (including biosimilar) and other targeted therapies in the UK to monitor the long-term safety of these drugs.
To find out more about the study, please visit our main site.
Latest blog posts
The impact of your data
Have you ever wondered where the data you provide are used?Whether you are a participant in the study, or an NHS professional who provides the data to BSRBR-RA, the answer is the same. This data is vital in the ongoing research into the long-term safety of biologic,...
BSRBR-RA Review of 2024
2024 has been another great year for BSRBR-RA. We’re very grateful to the NHS professionals who provide data, and to the participants. The data provided is integral to the success of the research.Our year in numbersOur publications this year Association between body...
How body weight affects the way people with rheumatoid arthritis react to treatment with tocilizumab
Dr Simon Tsoi investigated the association between body weight and tocilizumab effectiveness in rheumatoid arthritis, using data from the BSRBR-RA study. The results were published in the Rheumatology journal. What was already known?Tocilizumab is a type of treatment...
Adverse Events and the BSRBR-RA Study
How are adverse event data collected on the BSRBR-RA Study?An adverse event is “any untoward medical occurrence in a patient being administered a pharmaceutical product, which does not necessarily have a causal relationship with the product.”Details of adverse events...
Register Champions at the BSRBR-RA
When did you start recruiting for the RA register? Our site has been recruiting to the BSRBR-RA intermittently since 2003 but the Covid pandemic, the introduction of the online database and the need for regulatory alignment caused a pause of three and a half years. We...
Training Sessions at the BSRBR-RA
 The increasing use of Microsoft Teams for video calling has been really useful for us on the BSRBR-RA study, as it has widened our ability to support our NHS sites and provide useful training.We run three regular training sessions for our sites. Overview SessionThe...
JAK Inhibitors in the BSRBR-RA
Read about some of the recent research from BSRBR-RA looking at JAK inhibitors. Bit of background about you Hello, my name is Zixing Tian, I am an epidemiologist with a research focus on rheumatoid arthritis (RA). I work on the BSRBR-RA study, where I recently...
Working With Patient Support Organisations – Why Is This Important?
The BSRBR-RA study is fortunate to have strong links with a national patient organisation, National Rheumatoid Arthritis Society (NRAS), and have held numerous focus groups, surveys and meetings with them to ensure that the patient voice is always considered within...
New results from the study: Research on bDMARDs and Rheumatoid Arthritis
We are happy to share our latest research findings: 'Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs: does line of therapy matter?' This analysis, performed by Dr Kim Lauper,...
Read about some of the recent research from that BSRBR-RA looking at biosimilars.
Lianne, you did the research, tell us about yourself…Hello, my name is Lianne, I am an epidemiologist at the University of Manchester. For the past 12 years I have been a researcher working on the BSRBR-RA study. In addition, I also have a research interest in the...
Contact Us
+44 (0) 161 306 6000
Recent Comments